REVIEW
|
doi:10.20944/preprints202106.0609.v1
Subject:
Medicine And Pharmacology,
Immunology And Allergy
Keywords:
Chronic myeloid leukaemia; chronic phase; Tyrosine kinase inhibitor; Treatment free remission; deep molecular response; BCR-ABL.
Online: 25 June 2021 (08:13:40 CEST)